Longitudinal quality of life analysis in a phenylketonuria cohort provided sapropterin dihydrochloride

Health and Quality of Life Outcomes

Rani H Singh³  Julie A Kable⁴  Usha Ramakrishnan²  Teresa D Douglas¹ 

[1] Nutrition and Health Sciences Program, Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, Atlanta, GA USA;Hubert Department of Global Health, Emory University Rollins School of Public Health, 1518 Clifton Road NE. Room 7009, Atlanta, GA 30322, USA;Metabolic Nutrition Program, Division of Medical Genetics, Emory Department of Human Genetics, 2165 North Decatur Road, Decatur, GA 30033, USA;Division of Autism and Related Disorders, Department of Pediatrics, Emory University School of Medicine, Atlanta GA, USA

关键词: Medical diet;    BH4;    Tetrahydrobiopterin;    Sapropterin;    Quality of life;    PKU;    Phenylketonuria;   

Others  :  821892
DOI  :  10.1186/1477-7525-11-218

 received in 2013-08-21, accepted in 2013-12-20,  发布年份 2013

【 摘 要 】

Background

Sapropterin dihydrochloride effectively lowers plasma phenylalanine (Phe) for at least a third of phenylketonuria (PKU) patients, with potential for increased dietary Phe tolerance and decreased medical food requirement.

Objective

To investigate long-term quality of life (QOL) in patients with phenylketonuria (PKU) who took sapropterin (BH4, Kuvan®) for up to one year.

Methods

37 PKU patients, ages 10–49 years, were asked to complete a PKU-specific self-report QOL questionnaire (QOLQ) at baseline, 1, 4, 8, and 12 months. Questions were scored on a 5-point Likert scale under 5 sub-sections measuring Impact, Worries, Satisfaction, Support, and General wellbeing in relation to PKU. Responders with a plasma Phe decrease ≥ 15% after 1 month on sapropterin remained on the drug; Nonresponders ceased sapropterin after the trial month. Responders able to relax medical diet and maintain plasma Phe control were classified as Definitive; Responders unable to relax medical diet were classified as Provisional. All patients were routinely monitored by a registered dietitian. Data was analyzed in SPSS 19.0 using regression techniques.

Results

Of 17 Responders, 11 could maintain adequate Phe control on a less restrictive diet. One year mean Impact sub-score trends improved significantly for all sapropterin response groups, with greatest improvement among Definitive Responders (p < 0.0001). Satisfaction sub-scores also improved for Definitive Responders (p = 0.001). Trends for Total QOL score improved significantly over time for both Definitive (p = 0.001) and Provisional Responders (p = 0.028). Improvements in Definitive Responder scores were associated with increased Phe tolerance (Impact: p < 0.0001, Satisfaction: p = 0.022, Total QOL: p = 0.005) and MF adjustment (Satisfaction: p = 0.014, Total QOL: p = 0.026). Other sub-section scores remained steady, unaffected by sapropterin response or diet modification.

Conclusion

Increased Phe tolerance and reduced MF requirement in sapropterin Definitive Responders improves QOL perception across one year, specifically for life impact and satisfaction.

【 授权许可】

   
2013 Douglas et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Bilginsoy C, et al.: Living with phenylketonuria: Perspectives of patients and their families. J Inherit Metab Dis 2005, 28:639-649.
• [2]Legge FF: Phenylketonuria–the lived experience. J New Zealand Med Assoc 2007, 120:U2728.
• [3]Durham-Shearer SJ, Judd PA, Whelan K, Thomas JE: Knowledge, compliance and serum phenylalanine concentrations in adolescents and adults with phenylketonuria and the effect of a patient-focused educational resource. J Hum Nutr Diet 2008, 21:474-485.
• [4]Aoki K, Ohwada M, Kitagawa T: Long-term follow-up study of patients with phenylketonuria detected by the newborn screening programme in Japan. J Inherit Metab Dis 2007, 30:608-608.
• [5]Burton BK, et al.: A diversified approach for PKU treatment: Routine screening yields high incidence of psychiatric distress in phenylketonuria clinics. Mol Genet Metab 2013, 108:8-12.
• [6]Arnold GL, et al.: Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria. J Inherit Metab Dis 2004, 27:137-143.
• [7]Weglage J, et al.: Deficits in selective and sustained attention processes in early treated children with phenylketonuria–result of impaired frontal lobe functions? Eur J Pediatr 1996, 155:200-204.
• [8]Sharman R, Sullivan K, Young R, McGill J: Biochemical markers associated with executive function in adolescents with early and continuously treated phenylketonuria. Clin Genet 2009, 75:169-174.
• [9]Azadi B, et al.: Executive dysfunction in treated phenylketonuric patients. Eur Child Adolesc Psychiatry 2009, 18:360-368.
• [10]Christ SE, et al.: Inhibitory control in children with phenylketonuria. Dev Neuropsychol 2006, 30:845-864.
• [11]Stemerdink BA, et al.: Behaviour and school achievement in patients with early and continuously treated phenylketonuria. J Inherit Metab Dis 2000, 23:548-562.
• [12]Simon E, et al.: Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual Life Outcomes 2008, 6:25.
• [13]Bik-Multanowski M, et al.: Quality of life in noncompliant adults with phenylketonuria after resumption of the diet. J Inherit Metab Dis 2008, 31(Suppl 2):S415-S418.
• [14]Gassio R, et al.: Do adult patients with phenylketonuria improve their quality of life after introduction/resumption of a phenylalanine-restricted diet? Acta Paediatr 2003, 92:1474-1478.
• [15]Utz JR, et al.: START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients. Mol Genet Metab 2012, 105:193-197.
• [16]Singh RH, Quirk ME: Using change in plasma phenylalanine concentrations and ability to liberalize diet to classify responsiveness to tetrahydrobiopterin therapy in patients with phenylketonuria. Mol Genet Metab 2011, 104:485-491.
• [17]Ingersoll M: A modified quality-of-life measure for youths: psychometric properties. Diabetes Educ 1991, 17:114-118.
• [18]Singh RH, et al.: Impact of a Camp Experience on Phenylalanine Levels, Knowledge, Attitudes, and Health Beliefs Relevant to Nutrition Management of Phenylketonuria in Adolescent Girls. J Am Diet Assoc 2000, 100:797-803.
• [19]Cohen J, Cohen P, West SG, Aiken LS: Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988.
• [20]RH Heck SLT, Tabata LN, Heck RH SLT, Tabata LN: Multilevel and longitudinal modeling with IBM SPSS. In G.A. Marcoulides. 1st edition. Edited by Quantitative Methodology Series. New York: Routledge; 2010:343.
• [21]Cotugno G, et al.: Adherence to diet and quality of life in patients with phenylketonuria. Acta Paediatr 2011, 100:1144-1149.
• [22]Ziesch B, et al.: Tetrahydrobiopterin (BH(4)) in PKU: effect on dietary treatment, metabolic control, and quality of life. J Inherit Metab Dis 2012, 35:983-992.
• [23]Bosch AM, et al.: Remarkable differences: the course of life of young adults with galactosaemia and PKU. J Inherit Metab Dis 2009, 32:706-712.
• [24]Landolt MA, et al.: Quality of life and psychologic adjustment in children and adolescents with early treated phenylketonuria can be normal. J Pediatr 2002, 140:516-521.
• [25]Gourin CG: Quality of life is more than the sum of its parts. Otolaryngol Head Neck Surg 2008, 139:273-274.
• [26]Fryback DG, et al.: US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med Care 2007, 45:1162-1170.
• [27]Hanmer J, et al.: Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 2006, 26:391-400.
• [28]Wagner VM, et al.: Age, metabolic control and type of insulin regime influences health-related quality of life in children and adolescents with type 1 diabetes mellitus. Eur J Pediatr 2005, 164:491-496.